Beta Bionics (BBNX) Stock News

A securities fraud class action lawsuit has been filed against Beta Bionics (BBNX). The complaint alleges the company failed to disclose serious FDA safety issues with its iLet device, including over 18,000 complaints of life-threatening hypoglycemic events that were not properly investigated or reported. The class period is July 30, 2025 to February 24, 2026. Lead plaintiff deadline is November 3, 2026.

Jefferies initiated coverage on Beta Bionics (BBNX) with a Buy rating.

Jefferies began covering the diabetes technology company with a Buy recommendation.

A securities class action lawsuit has been filed against Beta Bionics (BBNX) alleging the company failed to disclose safety issues with its iLet insulin pump, including dangerous insulin dosing and unreported complaints to the FDA. Investors who purchased stock between July 30, 2025 and February 24, 2026 have until November 3, 2026 to seek lead plaintiff status.

Barclays started coverage on Beta Bionics (BBNX) with an Overweight rating and a $30 price target.

A securities class action has been filed against Beta Bionics (BBNX) alleging the company misled investors about FDA compliance for its iLet insulin delivery system. The class period runs July 30, 2025 to February 24, 2026. Lead plaintiff deadline is November 3, 2026.

A securities class action has been filed against Beta Bionics (BBNX) alleging the company misled investors about safety complaints regarding its iLet automated insulin delivery system. The FDA issued a warning letter in January 2026 citing failures to investigate and report serious adverse events. The class period runs July 30, 2025 to February 24, 2026. Lead plaintiff deadline is November 3, 2026.